# Phase 1 Myelodysplastic Syndromes trials: 61 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 61 trials in phase 1 for Myelodysplastic Syndromes that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Myelodysplastic Syndromes trials: 61 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/myelodysplastic-syndromes

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 61
- Recruiting or not yet: 61
- Read on: November 19, 2026

## Trials

The 25 newest of 61, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929740 | Bioavailability and Bioequivalence Study of Ziftomenib in Participants With Relapsed/Refractory AML or MDS | Kura Oncology, Inc. | Phase 1 | Not yet recruiting | Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929740) |
| August 21, 2026 | NCT07780565 | Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome | M.D. Anderson Cancer Center | Phase 1 | Not yet recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780565) |
| August 11, 2026 | NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | University of Wisconsin, Madison | Phase 1 | Recruiting | Allogenic Stem Cell Transplantation, Myeloid Malignancies, Lymphoid Malignancies, Acute Myeloid Leukemia, Chronic... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758218) |
| July 30, 2026 | NCT07737769 | Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or... | University of Michigan Rogel Cancer Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737769) |
| May 29, 2026 | NCT07616089 | Phase I Study of FXS0683 in the Treatment of Blood Tumors | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616089) |
| May 7, 2026 | NCT07573111 | Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem... | Laguna Biotherapeutics, Inc. | Phase 1 | Recruiting | Acute Leukemia, Myelodysplastic Syndrome | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573111) |
| May 4, 2026 | NCT07565220 | Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Leukemia, Myelodysplastic Syndrome(MDS)... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07565220) |
| January 16, 2026 | NCT07347418 | CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML | University of Colorado, Denver | Phase 1 | Recruiting | Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, AML (Acute... | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07347418) |
| December 24, 2025 | NCT07302776 | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT | Stanford University | Phase 1 | Recruiting | GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07302776) |
| December 15, 2025 | NCT07283094 | FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia | Montefiore Medical Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283094) |
| December 8, 2025 | NCT07270978 | Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS | University of Virginia | Phase 1 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07270978) |
| November 28, 2025 | NCT07254793 | Prophylactic DLI-X for Leukemia Relapse After HCT | University of Arizona | Phase 1 | Recruiting | Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254793) |
| August 6, 2025 | NCT07107126 | Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes | Remedy Plan, Inc. | Phase 1 | Recruiting | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07107126) |
| July 1, 2025 | NCT07044544 | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies | University of Alabama at Birmingham | Phase 1 | Recruiting | Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044544) |
| June 13, 2025 | NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing... | City of Hope Medical Center | Phase 1 | Recruiting | Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020533) |
| May 30, 2025 | NCT06996119 | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease... | City of Hope Medical Center | Phase 1 | Recruiting | Acute Myeloid Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06996119) |
| April 1, 2025 | NCT06904066 | Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic... | National Cancer Institute (NCI) | Phase 1 | Recruiting | Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms... | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06904066) |
| February 26, 2025 | NCT06846606 | Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Auron Therapeutics, Inc. | Phase 1 | Recruiting | Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Relapsed/Refractory AML, Relapsed... | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06846606) |
| February 11, 2025 | NCT06820268 | A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 | Recruiting | B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06820268) |
| December 2, 2024 | NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | Mayo Clinic | Phase 1 | Recruiting | Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712810) |
| October 24, 2024 | NCT06656494 | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 | Recruiting | Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS) | 266 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06656494) |
| September 27, 2024 | NCT06616636 | A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid... | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06616636) |
| September 19, 2024 | NCT06594445 | HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML | Masonic Cancer Center, University of Minnesota | Phase 1 | Recruiting | Myeloid Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06594445) |
| August 13, 2024 | NCT06551584 | Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT | Stanford University | Phase 1 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06551584) |
| August 13, 2024 | NCT06550713 | A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06550713) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| City of Hope Medical Center | 5 |
| Dana-Farber Cancer Institute | 4 |
| Montefiore Medical Center | 3 |
| M.D. Anderson Cancer Center | 3 |
| Mayo Clinic | 2 |
| National Cancer Institute (NCI) | 2 |
| University of Alabama at Birmingham | 2 |
| [Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-fosun-pharmaceutical-industrial-development-co-ltd) | 2 |
| Fred Hutchinson Cancer Center | 2 |
| University of Wisconsin, Madison | 2 |
| Stanford University | 2 |
| [Taiho Oncology, Inc.](https://specstream.ai/data/clinical-trials/company/taiho-oncology-inc) | 2 |
| Institut de Recherches Internationales Servier | 1 |
| Medical College of Wisconsin | 1 |
| Clinical Hub for Interventional Research (CHOIR) | 1 |
| Minovia Therapeutics Ltd. | 1 |
| [Taiho Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/taiho-pharmaceutical-co-ltd) | 1 |
| Remix Therapeutics | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Kura Oncology, Inc. | 1 |
| Edgewood Oncology Inc. | 1 |
| Vanderbilt-Ingram Cancer Center | 1 |
| Celyad Oncology SA | 1 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 1 |
| University of Colorado, Denver | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 51 |
| China | 6 |
| France | 2 |
| Australia | 2 |
| Armenia | 2 |
| Bulgaria | 2 |
| Lithuania | 2 |
| Poland | 2 |
| Romania | 2 |
| Slovakia | 2 |
| Spain | 2 |
| Israel | 1 |
| Japan | 1 |
| Belgium | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B domestic trade companies in the United States](https://specstream.ai/data/businesses/b2b-domestic-trade-companies/united-states)
- [Truck repair shops in the United States](https://specstream.ai/data/businesses/truck-repair-shops/united-states)
- [Resorts in the United States](https://specstream.ai/data/businesses/resorts/united-states)
- [Occupational safety services in the United States](https://specstream.ai/data/businesses/occupational-safety-services/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Farm insurance companies in the United States](https://specstream.ai/data/businesses/farm-insurance-companies/united-states)
